Abstract: Objective:To study the expression and clinical significance of TrkA splicing isoforms in human neuroblasto -ma. Methods:Data from 39patients with neuroblastoma were studied retrospectively. Expression of TrkA mRNA isoforms was detected by SYBR GreenI fluorescence quantitative PCR in the 39cases. The differences in TrkA splicing isoform ex-pression in different clinical stages were tested with t-test. Kaplan-Meier methods were used to estimate the 5-year survival rate. For univariate analysis, Kaplan-Meier survival analysis was used to establish the 5-year survival rate from the time of diagnosis, and log-rank statistical analysis was used to test the significance in the differences in 5-year survival rates be-tween subgroups of patients. Analysis of multiple variables was performed using the COX regression method. The factors examined included clinical variables (age, sex, primary site of tumor, metastatic sites, and stages), ratio between TrkAⅠ/Ⅱ expression and TrkAⅢexpression.Results: TrkAⅠ/Ⅱexpression in tumors of a lower stage was significantly higher than in tumors of a higher stage ( P<0.01), while the expression of TrkA Ⅲin lower stage tumors was significantly lower than in the higher stage tumors (P<0.01). Univariate analysis showed that the 5-year survival rate of patients with age > 1 year, ab -dominal origin, bone metastasis, Evans Ⅲ- Ⅳstage, lower TrkA Ⅰ/Ⅱto TrkAⅢratio was significantly lower than that of the control group. Multivariate analysis demonstrated that only the bone metastasis and lower TrkAⅠ/Ⅱto TrkA Ⅲratio had negative effects on the 5-year survival rate of patients with neuroblastoma. Conclusion:TrkAⅠ/Ⅱwas highly expressed in NB with good prognosis, while TrkAⅢwas highly expressed in NB with poor prognosis. Early detection of TrkA gene ex -pression and bone scanning are important for evaluation of the outcomes of neuroblastoma.